stockrowFortrea Holdings Inc.
FTRE Healthcare Biotechnology
Fortrea Holdings Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 1.00% from fiscal 2024.
- Revenue
- −1.40%
- EPS
- +103.7%
- Free cash flow
- −34.0%
- Total debt
- −6.33%
Quarter to September 2026, against a year earlier
Follow FTRE
Alert me
Fortrea Holdings Inc. (FTRE) EV/EBITDA
As of 6 November 2026, Fortrea Holdings Inc. (FTRE) trades at a EV/EBITDA of 32.1×. Over the past ten years it has ranged from 0.0× (December 2025) to 775× (January 2026); the current reading is higher than 60% of that period. That is above the Biotechnology industry median of 0.7× and above the Healthcare sector median of 8.5×.
EV/EBITDA, daily
Embed this chart
Annual newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| FY2025 | 743× | — |
| FY2024 | 0.0× | — |
| FY2023 | 31.7× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | EV/EBITDA | Change |
|---|---|---|
| Sep 2026 | 30.0× | (20.21%) |
| Jun 2026 | 37.6× | (33.82%) |
| Mar 2026 | 56.8× | (92.36%) |
| Dec 2025 | 743× | — |
| 13 more quarters | Free account |
Against its own ten years
EV/EBITDA against peers
| Company | EV/EBITDA |
|---|---|
| BHVN Biohaven Ltd. compare | n/m |
| VIR Vir Biotechnology, Inc. compare | n/m |
| TRAX First Tracks Biotherapeutics, Inc. compare | n/m |
| REPL Replimune Group, Inc. compare | n/m |
| ZYME Zymeworks Inc. compare | n/m |
| IMNM Immunome, Inc. compare | n/m |
| SRPT Sarepta Therapeutics, Inc. compare | n/m |
| HRMY Harmony Biosciences Holdings, Inc. compare | 5.4× |
| FTRE Fortrea Holdings Inc. | 32.1× |
| Biotechnology industry median | 0.7× |
| Healthcare sector median | 8.5× |
| Market median | 10.9× |
What EV/EBITDA is
Enterprise Value over EBITDA tells an investor how the market values a whole company, with debt added and cash taken off, against its operating earnings.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ EBITDA (TTM)